ARMATA PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent, Diluted
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Net Income (Loss) Attributable to Parent, Diluted of -$3.62 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-06.
Discontinued › Income Statement
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2019-05-06
- ARMATA PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2019-03-31 was -$3.62M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-09-30 was -$1.63M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-06-30 was -$3.05M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-03-31 was -$3.13M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2019-03-31 | -$3.62M 10-Q · filed 2019-05-06 | ||
| 2018-09-30 | -$1.63M 10-Q · filed 2018-11-08 | -$4.68M derived: sum of 2 quarters · filed 2018-11-08 | -$7.79M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$3.05M 10-Q · filed 2018-08-09 | -$6.18M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$3.13M 10-Q · filed 2019-05-06 | ||
| 2017-09-30 | -$779.00K 10-Q · filed 2018-11-08 | -$8.82M derived: sum of 2 quarters · filed 2018-11-08 | -$12.03M 10-Q · filed 2018-11-08 |
| 2017-06-30 | -$8.04M 10-Q · filed 2018-08-09 | -$11.29M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |